ArticleNature2021
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 274 papers.
0numbers the graph read from it
0cells of the map it votes in
274citing papers in PubMed
25.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
274 citing papers in PubMed, 435 citations in OpenAlex.
- Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.BMC infectious diseases · 2025Trial
- Lipid flip-flop in biological membranes: through the lens of TMEM16F.Physiological reviews · 2027Review
- Syncytium-forming HSV-1 in cancer gene therapy: From molecular mechanisms to clinical translation.Virulence · 2026Review
- TMEM16F deficiency alleviates sepsis-induced acute lung injury through regulating macrophage polarization.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Viral syncytia evolve to resist interferon.Nature communications · 2026Article
- Recent advances in TMEM16F: structural plasticity, functional versatility, and implications for human diseases.Cell communication and signaling : CCS · 2026Review
- Observational
- Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.Journal of virology · 2026Article
- TNF inhibits SARS-CoV-2 induced cell-cell fusion through activating the SDC4-RhoA signaling to promote actin bundles formation.Cell insight · 2026Article
- Calcium dependent activation of the TMEM16F scramblase and ion channel.Nature structural & molecular biology · 2026Article
- Targeting virus-interacting host ion channels as a novel antiviral strategy.Acta pharmacologica Sinica · 2026Review
- Dynamic metabolic modelling of ATP allocation during viral infection.Journal of the Royal Society, Interface · 2026Article
- Single-Target Pairing System (StarPair) for Large-Scale Interrogation of Cell-Cell Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Emerging Promise of Pentacyclic Triterpenoid Derivatives as Novel Antiviral Agents Against SARS-CoV-2 Variants.Molecules (Basel, Switzerland) · 2026Review
- A Brief Introduction into the Biological Phenomenon of Cell-Cell Fusion.Advances in experimental medicine and biology · 2026Review
- Droplet-based single-cell pairing for high-throughput interaction mapping of antigen-receptor combinations.Science advances · 2025Article
- MISO: microfluidic protein isolation enables single-particle cryo-EM structure determination from a single cell colony.Nature methods · 2025Article
- LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.Cell proliferation · 2025Article
- Nasal mucus-derived KLK13 restricts SARS-CoV-2 infection via proteolytic cleavage of spike.mBio · 2025Article
- A cell-based scrambling assay reveals the phospholipid headgroup preference of TMEM16F on the plasma membrane.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
214 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 3 countries.
Luca Braga *King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
Hashim Ali *King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.ORCID http://orcid.org/0000-0002-5056-845X
Ilaria SeccoKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
Elena ChiavacciKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
Guilherme NevesMRC Centre for Neurodevelopmental Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0001-6463-6997
Daniel GoldhillDepartment of Infectious Diseases, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-4597-5963
Rebecca PennDepartment of Infectious Diseases, Imperial College London, London, UK.
Jose M Jimenez-GuardeñoDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0002-1726-8033
Ana M Ortega-PrietoDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0002-9023-0103
Rossana BussaniDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Antonio CannatàKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.ORCID http://orcid.org/0000-0001-7609-6297
Giorgia RizzariKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.ORCID http://orcid.org/0000-0002-9001-5374
Chiara CollesiDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.ORCID http://orcid.org/0000-0003-3909-422X
Edoardo SchneiderKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.ORCID http://orcid.org/0000-0002-1147-1882
Daniele ArosioIstituto di Biofisica (IBF), Consiglio Nazionale delle Ricerche (CNR), Trento, Italy.ORCID http://orcid.org/0000-0003-2872-6906
Ajay M ShahKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
Wendy S BarclayDepartment of Infectious Diseases, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-3948-0895
Michael H MalimDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0002-7699-2064
Juan BurroneMRC Centre for Neurodevelopmental Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Mauro GiaccaKing's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK. mauro.giacca@kcl.ac.uk.ORCID http://orcid.org/0000-0003-2927-7225
King's College London · GBImperial College London · GBUniversity of Trieste · ITInstituto di Biofisica · ES
Funding
X-ray Crystallographic Fragment Screening CoreU54AI150472 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ARNOLD, EDWARD · 2019 to 2021
$15.7MUltrapotent Inhibitors of Wild-type and Multi-drug Resistant HIVR01AI076119 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G · 2008 to 2018
$4.1MUltrapotent Inhibitors of Wild-type and Multi-drug Resistant HIVR37AI076119 · NIAID · EMORY UNIVERSITY · PI Stefan G Sarafianos · 2020 to 2026
$3.6MBritish Heart Foundation CH/1999001/11735British Heart Foundation RE/18/2/34213British Heart Foundation RG/19/11/34633British Heart Foundation RG/20/3/34823European Research Council 787971Medical Research Council MR/N026063/1Medical Research Council MR/W006251/1NIAID NIH HHS R01 AI076119NIAID NIH HHS R37 AI076119NIAID NIH HHS U54 AI150472Wellcome Trust 106223Wellcome Trust 106223/Z/14/ZWellcome Trust 215508Wellcome Trust 215508/Z/19/Z
Abstract
COVID-19 is a disease with unique characteristics that include lung thrombosis
Indexed as
Cell FusionDrug Evaluation, PreclinicalAgedAged, 80 and overAlveolar Epithelial CellsAnimalsAnoctaminsCalcium SignalingCell LineChloride ChannelsChlorocebus aethiopsCOVID-19FemaleGiant CellsHumansLungAnoctaminsChloride ChannelsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.